Genitourinary Cancers

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Latest News

Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs | Image Credit: © Katsyarina - stock.adobe.com

NMPA Approves Belzutifan for VHL in RCC, CNS Hemangioblastomas, or pNETs

By Kyle Doherty

November 22nd 2024

The NMPA has approved belzutifan for von Hippel-Lindau disease in RCC, CNS hemangioblastomas, or pNETs not requiring immediate surgery.

Sandy Srinivas, MD, of Stanford Medicine

Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents

By Megan Hollasch

November 21st 2024

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

By Ashley Chan

November 9th 2024

PD-L1, KIM-1 Expression in ccRCC | Image Credit: © Cornflakesei - stock.adobe.com

PD-L1, KIM-1 Expression Are Predictive of Outcomes With Adjuvant Nivolumab Alone, Plus Ipilimumab in ccRCC

By Gina Mauro

November 8th 2024

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors

By Gina Mauro

November 7th 2024

Latest CME Events & Activities

26th Annual International Lung Cancer Congress®

July 25-26, 2025

PER LIVER CANCER TUMOR BOARD: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable ...

November 16, 2024

Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease

Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition

December 6, 2024

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

18th Annual New York GU Cancers Congress™

March 28-29, 2025

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

More News

Dr. Vaishampayan on the Safety of Tivozanib Versus Sorafenib in RCC

By Ulka N. Vaishampayan, MBBS, FAB

September 15th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the safety of tivozanib versus sorafenib in advanced renal cell carcinoma.

$Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC$

Dr. Pal on the Benefit of Tivozanib in Later-Line Settings for Refractory RCC

By Sumanta Kumar Pal, MD

September 10th 2020

Sumanta K. Pal, MD, discusses the benefit of tivozanib in later-line setting treatment settings for patients with refractory renal cell carcinoma.

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

By Ulka N. Vaishampayan, MBBS, FAB

September 9th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Analysis Identifies Immunogenomic Determinants of Response and Survival in RCC

By Jessica Hergert

September 9th 2020

David A. Braun, MD, PhD, discusses findings from a pooled analysis of 3 clinical trials evaluating the potential impact of immunophenotypes, somatic mutations, and chromosomal alterations on response to PD-1 inhibition and recurrence in patients with renal cell carcinoma.

Dr. McGregor on the Need to Develop Novel Targets in RCC

By Bradley McGregor, MD

September 8th 2020

Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.

Dr. Vaishampayan on the Need to Develop Novel Therapies in mRCC

By Ulka N. Vaishampayan, MBBS, FAB

September 3rd 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma.

Dr. Motzer on the TIVO-3 Trial Examining Tivozanib in Advanced RCC

By Robert J. Motzer, MD

September 2nd 2020

Robert J. Motzer, MD, discusses the results of the phase 3 TIVO-3 trial with tivozanib versus sorafenib in patients with advanced renal cell carcinoma.

GU Experts Review Treatment Options, Remaining Challenges, and Future Research in Penile Cancer

By OncLive Staff

August 31st 2020

Today, we had the pleasure of sitting down with a group of experts in genitourinary cancers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Moffitt Cancer Center to discuss a malignancy that is not often an everyday focus: penile cancer.

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

By Ulka N. Vaishampayan, MBBS, FAB

August 27th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of axitinib and pembrolizumab in advanced renal cell carcinoma.

FDA Approval Insights: Avelumab in Metastatic Urothelial Carcinoma

By OncLive Staff

August 27th 2020

In our exclusive interview, Shilpa Gupta, MD, of Cleveland Clinic, discusses the FDA approval of avelumab in metastatic urothelial carcinoma and key findings from the JAVELIN Bladder 100 study.

Ilixadencel Plus Sunitinib Shows Survival Benefit in Metastatic RCC

By Kristi Rosa

August 26th 2020

The combination of the off-the-shelf cancer immune primer Ilixadencel and sunitinib has demonstrated promising survival benefit when used as a frontline treatment for newly diagnosed patients with metastatic renal cell carcinoma.

Bright Future in Advanced Urothelial Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Sequencing Considerations in mUC after Frontline IO

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Metastatic Bladder Cancer: Progression After Maintenance

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Educating Patients on Maintenance Therapy in mUC

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Changing the Standard of Care in Metastatic Bladder Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Practical Management of AEs in Metastatic Bladder Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Safety Data from JAVELIN Bladder 100

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Increased Survival Outcomes with Switch Maintenance in mUC

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Switch Maintenance Strategy for Metastatic Bladder Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Value of PD-L1 Testing in Metastatic Urothelial Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

PD-L1 Expression in Metastatic Urothelial Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Current Status of Therapy: Metastatic Urothelial Cancer

By Shilpa Gupta, MD, Cleveland Clinic
Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute

August 26th 2020

Dr. McGregor on the Evolving Treatment Landscape of RCC

By Bradley A. McGregor, MD

August 25th 2020

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Dr. Sonpavde on the Need for Phase 3 Data With Pembrolizumab or Atezolizumab in Bladder Cancer

By Guru P. Sonpavde, MD

August 24th 2020

Guru P. Sonpavde, MD, discusses the need for phase 3 data evaluating frontline pembrolizumab or atezolizumab in bladder cancer.

Dr. Chang on the Impact of COVID-19 on the Surgical Management of GU Cancers

By Steven Lee Chang, MD

August 24th 2020

Steven Lee Chang, MD, discusses the impact of the coronavirus disease 2019 on the surgical management of patients with genitourinary cancers.

FDA Approval Sought for Frontline Cabozantinib/Nivolumab Combo in Advanced RCC

By Gina Columbus

August 24th 2020

A supplemental new drug application has been submitted to the FDA for the combination of cabozantinib and nivolumab as a treatment for patients with advanced renal cell carcinoma.

RCC Care Continues to Evolve as the COVID-19 Crisis Rages On

By Brittany Cote

August 21st 2020

Toni K. Choueiri, MD, discusses the novel coronavirus disease, which continues to impact the care of patients with metastatic renal cell carcinoma and other cancers in a multitude of ways.